MYCN and neuroblastoma: Genomic amplification of the oncogene MYCN acts as an essential oncogenic event in high-risk NB, occurring in approximately 50% of high-risk cases, and MYCN amplification is strongly related to a poor NB prognosis (OS < 50%).